Worth reading
42Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Announced details
rogocekib（CTX-712）Explanatory videoSupplementary materials
Applicable field (uses covered by this announcement)
Relapsed or refractory acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), and other conditions
Launch date15 June 2026 (actual date of release of the explanatory video and supplementary materials)
Location (as indicated in this announcement)
Fujisawa, Kanagawa Prefecture (head office)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Source (materials cited by the company)
European Hematology Association (EHA) Annual Congress
| Item | Details |
|---|---|
| Names of Products / Services Covered | rogocekib（CTX-712）, Explanatory video, Supplementary materials |
| Launch date | 15 June 2026 (actual date of release of the explanatory video and supplementary materials) |
| Applicable area | Relapsed or refractory acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), and other conditions |
| Location | Fujisawa, Kanagawa Prefecture (head office) |
| Source | European Hematology Association (EHA) Annual Congress |
Items this document does not state (13)
CounterpartyCounterparty overviewRelationship with the CompanyContract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocation scaleQuantitative EffectsUsage historyImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To promote understanding among investors and the general public of the presentation at EHA 2026 and to answer questions received to date.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.